Royalty Report: Drugs, Pharmaceuticals, Biotechnology – Collection: 28859

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Biotechnology
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28859

License Grant
The Licensor hereby grants to Licensee an exclusive, worldwide License, including the right to grant sublicenses, under the Patent Rights to develop, have developed, make, have made, use, have used, import, have imported, offer for sale, sell and have sold Primary Licensed Products, and a nonexclusive License, including the right to grant sublicenses under the Patent Rights to develop, have developed, make, have made, use, have used, import, have imported, offer for sale, sell and have sold Secondary Licensed Products, and a commercial License to use the Biological Materials to develop, have developed, make, have made, use, and have used any Licensed Product for the Term.
License Property
The Licensor is the owner of certain Patent Rights and of Biological Materials to establish a program to develop therapeutic and/or diagnostic products relating to Activin Receptors (Type IIB).

U.S. Patent No. 5,885,794 issued March 23, 1999, Cloning and Recombinant Production of Receptor(s) of the Activin/TGF-B Superfamily

U.S. Patent No. 6,162,896 issued December 19, 2000, Recombinant Vertebrate Activin Receptors,

U.S. Application Serial No. 09/742,684, filed December 19, 2000.Cloning and Recombinant Production of Receptor(s) of the Activin/TGF-B Superfamily,

Development of ActRIIa and/or ActRlIb as Human Therapeutics for the Treatment of Muscle Wasting Disorders

IPSCIO Record ID: 7481

License Grant
Licensor hereby grants to Licensee a worldwide exclusive royalty bearing license in the Field to the non-exclusive rights held by Licensor with respect to the TGF-B Antibody Patent Rights to (i) use the TGF-B Antibody Know How, and (ii) to make, have made, use, offer to sell, sell or import into the United States Licensed Product(s) or use Licensed Method(s) in the Territory in which the TGF-B Antibody Patent Rights are effective until the end of the full term(s) for which these Patent Rights are issued, unless sooner terminated as hereinafter provided.
License Property
Licensor is a biopharmaceutical company that is the owner of a certain patent and patent applications and know how relating to monoclonal antibodies that bind Transforming Growth Factor B ('TGF-B'), specifically TGF-B1 and TGF-B2.

Biological Property shall mean any DNA materials, derivatives of such DNA materials, cell lines and peptides containing the DNA materials or derivatives thereof, that are related to the TGF-B Antibody Patent Rights, and to the TGF-B Receptor Patent Rights, respectively.

TGF-B Antibody Patent Rights shall mean the Patent Rights that relate to monoclonal antibodies that bind Transforming Growth Factor ('TGF-B'), specifically TGF-B1 and TGF-B2.

TGF-B Receptor Patent Rights Licensed from MIT shall mean the Patent Rights that relate to TGF-B receptors, including TGF-B type II and TGF-B type III receptors, cDNA of the respective receptors, and methods of use.

Field of Use
Field shall mean uses for any and all purposes with the following exceptions: (i) opthamology, (ii) the TGF-B Antibody Rights previously licensed to Genentech, Inc., and (iii) with respect to the TGF-B Receptor Patent Rights Licensed from MIT only, those rights previously exclusively sublicensed by CELTRIX to R&D Systems.

IPSCIO Record ID: 28866

License Grant
Licensee entered into a license agreement with a undsclosed Non-profit Institution for an exclusive, sublicensable, worldwide license to certain patents developed by the institution.
License Property
The Licensed technology includes sotatercept and for ACE-536.

Sotatercep tis a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss.

ACE-536 is an investigational protein therapeutic that increases red blood cell levels by targeting molecules in the TGF-β superfamily being developed ACE-536 to treat anemia in patients with rare blood disorders, including β-Thalassemia and myelodysplastic syndromes .

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.